S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
How to Invest in AI's Fast-Growing Market (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
How to Invest in AI's Fast-Growing Market (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Dollar General May Create an Opportunity for Patient Investors
How to Invest in AI's Fast-Growing Market (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
How to Invest in AI's Fast-Growing Market (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
How to Invest in AI's Fast-Growing Market (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Dollar General May Create an Opportunity for Patient Investors
How to Invest in AI's Fast-Growing Market (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
How to Invest in AI's Fast-Growing Market (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
How to Invest in AI's Fast-Growing Market (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Dollar General May Create an Opportunity for Patient Investors
How to Invest in AI's Fast-Growing Market (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
How to Invest in AI's Fast-Growing Market (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
How to Invest in AI's Fast-Growing Market (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Dollar General May Create an Opportunity for Patient Investors
How to Invest in AI's Fast-Growing Market (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
NASDAQ:UTHR

United Therapeutics (UTHR) Stock Forecast, Price & News

$218.88
+1.66 (+0.76%)
(As of 06/5/2023 ET)
Compare
Today's Range
$215.29
$219.87
50-Day Range
$205.19
$232.99
52-Week Range
$201.65
$283.09
Volume
278,501 shs
Average Volume
367,145 shs
Market Capitalization
$10.25 billion
P/E Ratio
14.74
Dividend Yield
N/A
Price Target
$294.67

United Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
34.6% Upside
$294.67 Price Target
Short Interest
Healthy
2.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
1.20mentions of United Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$42.22 M Sold Last Quarter
Proj. Earnings Growth
9.11%
From $18.33 to $20.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.20 out of 5 stars

Medical Sector

10th out of 985 stocks

Pharmaceutical Preparations Industry

3rd out of 483 stocks


UTHR stock logo

About United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Stock News Headlines

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (UTHR)
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Is There Still Time to Get In On the Lithium Boom?
"Lithium demand from the electric vehicle (EV) industry is growing at twice the rate of lithium production. By 2030, experts predict that 26 million EVs will be on U.S. roads, up from around 600,000 today. That's why new government incentives have been put in place to support more urgently-needed "Made in America" lithium.
Is There Still Time to Get In On the Lithium Boom?
"Lithium demand from the electric vehicle (EV) industry is growing at twice the rate of lithium production. By 2030, experts predict that 26 million EVs will be on U.S. roads, up from around 600,000 today. That's why new government incentives have been put in place to support more urgently-needed "Made in America" lithium.
The Latest Analyst Ratings for United Therapeutics
Q1 2023 United Therapeutics Corp Earnings Call
Why United Therapeutics Shares Are Falling Today
See More Headlines

UTHR Price History

UTHR Company Calendar

Last Earnings
5/03/2023
Today
6/06/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
965
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$294.67
High Stock Price Forecast
$375.00
Low Stock Price Forecast
$230.00
Forecasted Upside/Downside
+34.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$727.30 million
Pretax Margin
47.13%

Debt

Sales & Book Value

Annual Sales
$1.94 billion
Cash Flow
$17.21 per share
Book Value
$105.24 per share

Miscellaneous

Free Float
40,991,000
Market Cap
$10.25 billion
Optionable
Optionable
Beta
0.60

Social Links


Key Executives

  • Martine A. RothblattMartine A. Rothblatt
    Chairman & Chief Executive Officer
  • Michael Ian Benkowitz
    President & Chief Operating Officer
  • James Christopher Edgemond
    Treasurer, Chief Financial & Accounting Officer
  • Paul A. MahonPaul A. Mahon
    Secretary, Executive VP & General Counsel
  • Dewey Steadman
    Head-Investor Relations













UTHR Stock - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price forecast for 2023?

9 brokerages have issued 1 year price targets for United Therapeutics' shares. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they expect the company's share price to reach $294.67 in the next twelve months. This suggests a possible upside of 34.6% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2023?

United Therapeutics' stock was trading at $278.09 on January 1st, 2023. Since then, UTHR shares have decreased by 21.3% and is now trading at $218.88.
View the best growth stocks for 2023 here
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, May, 3rd. The biotechnology company reported $4.86 EPS for the quarter, beating the consensus estimate of $4.26 by $0.60. The biotechnology company earned $506.90 million during the quarter, compared to analysts' expectations of $514.37 million. United Therapeutics had a trailing twelve-month return on equity of 15.49% and a net margin of 36.76%. The firm's revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $5.03 EPS.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.14%), Wellington Management Group LLP (8.07%), Avoro Capital Advisors LLC (6.13%), FMR LLC (5.42%), Renaissance Technologies LLC (4.75%) and State Street Corp (3.83%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $218.88.

How much money does United Therapeutics make?

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.25 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $14.85 on an earnings per share basis.

How many employees does United Therapeutics have?

The company employs 965 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.

This page (NASDAQ:UTHR) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -